[New treatment options for autoimmune bullous diseases].

Authors

Nina van Beek, Enno Schmidt

Published in

Dermatologie (Heidelberg, Germany). Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Autoimmune bullous diseases are a heterogeneous group of diseases characterized by autoantibody deposits leading to split formation in the skin and mucous membranes; they are associated with a significant impairment of quality of life and increased mortality. Therapeutic options are limited and rely on broad immunosuppression, primarily the administration of topical or systemic glucocorticosteroids. Rituximab is also approved for moderate to severe pemphigus vulgaris. Due to the rarity of these conditions, the body of clinical research on pemphigus and pemphigoid diseases is limited. Current therapeutic approaches focus primarily on enhancing the efficacy of B‑cell depletion in pemphigus vulgaris/foliaceus, as well as on blocking specific inflammatory mediators in bullous pemphigoid. Further efforts are required to conduct more studies within this group of diseases and to fully realize the potential of more effective drugs with improved side-effect profiles.

PMID:
42771162
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.